HRS-4642 showed a tolerable safety profile and preliminary anti-tumor activity in advanced solid tumors harboring KRAS G12D mutation. Dose escalation is ongoing and expected to proceed to dose expansion soon. Clinical tria...
HRS-4642 showed a tolerable safety profile and preliminary anti-tumor activity in advanced solid tumors harboring KRAS G12D mutation. Dose escalation is ongoing and expected to proceed to dose expansion soon. Clinical trial identification NCT05533463....
Conclusions HRS-4642 showed a tolerable safety profile and preliminary anti-tumor activity in advanced solid tumors harboring KRAS G12D mutation. Dose escalation is ongoing and expected to proceed to dose expansion soon. Clinical trial identification NCT05533463. 本内容仅供医学专业人士参考相关...
Targeting cancers with KRAS-G12D mutations. Trends Cancer 9, 955-967. 2. Fell, J.B., Fischer, J.P., Baer, B.R., Blake, J.F., Bouhana, K., Briere, D.M., Brown, K.D., Burgess, L.E., Burns, A...
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy 2025, Molecular Cancer Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma 2025, Cancers RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms 2024, Journal ...